1. US Department of Health and Human Services, FDA, CDER, CVM.Guidance for the Industry: Bioanalytical Method Validation. Washington, DC: US Department of health and Human Services, FDA, CDER and CVM; 2001.
2. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation—a revisit with a decade of progress.Pharm Res. 2000;17:1551–1557.
3. DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules.Pharm Res. 2003;20:1885–1900.
4. Viswanathan CT, Bansal S, Booth B, et al. Workshop/conference report—quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.AAPS J [serial online]. 2007;9:E30-E42.
5. Yau M. Stability of samples, standards, QC's, and reagent: FDA perspective. Quantitative bioanalytical methods validation and implementation—best practices for chromatographic and ligand binding assays. Paper presented at the AAPS/FDA Workshop, May 2, 2006, Arlington, VA.